{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T18:18:18Z","timestamp":1649182698420},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3,1]]},"abstract":"<jats:title>Osteoporoza Uzrokovana Glukokortikoidima<\/jats:title><jats:p>Glukokortikoidi su lijekovi koji naj\u010de\u0161\u0107e uzrokuju osteoporozu, a u\u010dinci tih lijekova pobu\u0111uju sve ve\u0107u pozornost zbog njihove ra\u0161irene primjene u autoimunim, plu\u0107nim, gastrointestinalnim bolestima ili nakon transplantacije organa. Glukokortikoidna osteoporoza nastaje brzo, unutar nekoliko prvih mjeseci primjene glukokortikoida, vi\u0161e zahva\u0107a spu\u017evastu nego kortikalnu kost i brzo pove\u0107ava rizik nastanka prijeloma, poglavito kralje\u017eaka i kuka. U\u010dinci glukokortikoida na skelet ovisni su i o dozi i o trajanju terapije. Mehanizmi kojima glukokortikoidi dovode do osteoporoze su mnogobrojni i nisu jo\u0161 potpuno jasni. Usprkos postojanju vi\u0161e preporuka za otkrivanje i lije\u010denje glukokortikoidne osteoporoze i lijekova koji mogu smanjiti rizik prijeloma kralje\u017enice, jo\u0161 uvijek se razmjerno mali postotak bolesnika zadovoljavaju\u0107e dijagnosticira i lije\u010di.<\/jats:p>","DOI":"10.2478\/v10004-007-0004-8","type":"journal-article","created":{"date-parts":[[2007,4,2]],"date-time":"2007-04-02T16:38:54Z","timestamp":1175531934000},"page":"19-24","source":"Crossref","is-referenced-by-count":0,"title":["Glucocorticoid-Induced Osteoporosis"],"prefix":"10.2478","volume":"58","author":[{"given":"Bo\u017eidar","family":"\u010curkovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. <i>Arthritis Rheum<\/i> 1996;39:1791-801.","DOI":"10.1002\/art.1780391104"},{"key":"2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","article-title":"Glucocortcoid-induced osteoporosis: an update","volume":"17","author":"G Mazziotti","year":"2006","journal-title":"Trends Endocrnol Metab"},{"key":"3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-112-5-352","article-title":"Glucocorticoid-induced osteoporosis: pathogenesis and management","volume":"112","author":"B Lukert","year":"1990","journal-title":"Ann Intern Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ecl.2005.01.014","article-title":"Osteoporosis associated with excess glucocorticoids","volume":"34","author":"J Shaker","year":"2005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0950-3579(05)80080-9","article-title":"Corticosteroid osteoporosis","volume":"7","author":"I Reid","year":"1993","journal-title":"Bailliere Clin Rheumatol"},{"key":"6","author":"J Adachi","year":"2000","journal-title":"Primer on corticosteroid-induced osteoporosis"},{"key":"7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1359\/jbmr.2001.16.1.97","article-title":"Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis","volume":"16","author":"Dalle Carbonare","year":"2001","journal-title":"J Bone Miner Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"T Suda","year":"1999","journal-title":"Endocr Rev"},{"key":"9","first-page":"3441","article-title":"Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis","volume":"81","author":"E Canalis","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00002281-200307000-00013","article-title":"Mechanisms of glucocorticoid-induced osteoporosis","volume":"15","author":"E Canalis","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-006-0019-1","article-title":"The patogenesis, epidemiology and management of glucocorticoid-induced osteoporosis","volume":"79","author":"T Van Staa","year":"2006","journal-title":"Calcif Tissue Int"},{"key":"12","first-page":"422","article-title":"Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid arthritis register","volume":"43","author":"G Haugeberg","year":"2000","journal-title":"Arthritis Rheum"},{"key":"13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1136\/bmj.306.6877.558","article-title":"Risk of vertebral fracture in women with rheumatoid arthritis","volume":"306","author":"T Spector","year":"1993","journal-title":"Br Med J"},{"key":"14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/ard.60.5.521","article-title":"Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland","volume":"60","author":"T Huusko","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/qjmed\/93.2.105","article-title":"Use of oral corticosteroids in the United Kingdom","volume":"93","author":"T Van Staa","year":"2000","journal-title":"Q J Med"},{"key":"16","first-page":"68","article-title":"Primjena lijekova u bolesnika s reumatoidnim artritisom u realnom \u017eivotu","volume":"51","author":"A Filip\u010di\u0107","year":"2004","journal-title":"Reumatizam"},{"key":"17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.0306-5251.2001.bjcp.1385.x","article-title":"Public health imapct of adverse bone effects of oral corticosteroids","volume":"51","author":"T Van Staa","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"18","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Predictors and bone density treshold for vertebral fracture in patients using oral glucocorticosteroids","volume":"48","author":"T Van Staa","year":"2003","journal-title":"Arthritis Rheum"},{"key":"19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-anlysis of prior corticosteroid use and fracture risk","volume":"19","author":"J Kanis","year":"2004","journal-title":"J Bone Miner Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"T VanStaa","year":"2002","journal-title":"Osteoporosis Int"},{"key":"21","doi-asserted-by":"crossref","unstructured":"American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. <i>Arthritis Rheum<\/i> 2001;44:1496-503.","DOI":"10.1002\/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5"},{"key":"22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00002281-200307000-00016","article-title":"Effects of rheumatoid arthritis on bone","volume":"15","author":"G Haugeberg","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/ard.2003.018556","article-title":"How to prevent steroid induced osteoporosis","volume":"64","author":"P Sambrook","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"24","first-page":"225","article-title":"Osteoporosis in rheumatoid arthritis: a comparison between corticosteroid treated and non treated patients","volume":"73","author":"N Lakta\u0161i\u0107-\u017derjavi\u0107","year":"2006","journal-title":"Joint Bone Spine"},{"key":"25","unstructured":"Royal College of Physicians, National osteoporosis Society, Bone and Tooth Society of Great Britain. Glucocorticoid-induced osteoporosis - guidelines for prevention and treatment. London: Royal College of Physicians; 2002."},{"key":"26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis","volume":"339","author":"K Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids","volume":"44","author":"J Adachi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"87","author":"S Wallach","year":"2000","journal-title":"Calcif Tissue Inter"},{"key":"29","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis","volume":"102","author":"N Lane","year":"1998","journal-title":"J Clin Invest"},{"key":"30","first-page":"40","article-title":"Osteoporotic vertebral fractures in inflammatory rheumatic patients","volume":"suppl. I","author":"V Mu\u017ei\u0107","year":"2006","journal-title":"Zdravni\u0161ki vestnik"},{"key":"31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1479-8077.2006.00162.x","article-title":"Use of corticosteroids and bone-active medications in clinical practice","volume":"9","author":"J Zochling","year":"2006","journal-title":"APLAR J Rheumatol"}],"container-title":["Archives of Industrial Hygiene and Toxicology"],"original-title":[],"link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/aiht\/58\/1\/article-p19.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/view\/j\/aiht.2007.58.issue-1\/v10004-007-0004-8\/v10004-007-0004-8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T18:23:55Z","timestamp":1590863035000},"score":1,"resource":{"primary":{"URL":"https:\/\/content.sciendo.com\/doi\/10.2478\/v10004-007-0004-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,1]]},"references-count":31,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.2478\/v10004-007-0004-8","relation":{},"ISSN":["0004-1254"],"issn-type":[{"value":"0004-1254","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3,1]]}}}